Investors braced for a full earnings docket and the Federal Reserve's next policy decision this week.
Amber Barkley is a writer and editor with over 10 years of experience in topics ranging from personal finance to marketing analytics to fiction. She found her niche in personal finance in 2022, when ...
Amber Barkley is a writer and editor with over 10 years of experience in topics ranging from personal finance to marketing analytics to fiction. She found her niche in personal finance in 2022, when ...
Oruka Therapeutics, Inc. announced positive Week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe PsO. EVERLAST ...
ORKA-001 on track to advance into Phase 3 trials in 1H 2027. 52-week EVERLAST-A results on track for December 2026. ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis o ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results